BRUSSELS, April 22 Belgian biotech company
MDxHealth said on Monday two presentations set to be
delivered at a leading U.S. convention would confirm that its
prostate cancer test helps urologists rule out unnecessary
The molecular diagnostic company, which develops tests for
cancer, said two presentations would be made supporting its
ConfirmMDx test at the American Urology Association annual
meeting on May 4-8.
ConfirmMDx, MDxHealth's first commercial product, aims to
distinguish patients with a true-negative biopsy from those who
may have undetected cancer.
(Reporting by Philip Blenkinsop)